Pharma Pulse 6/20/24: Talkspace and FitOn Team Up, The Potential of CAR-T Therapies & more


The latest news for pharma industry insiders.

The Potential of CAR T Therapies: Q&A with Ying Huang

Legend Biotech revealed data collected from the CARTITUDE-2 Cohort D study at ASCO 2024 in Chicago in late May and early June of this year. The study is testing the ability of Carvykti to treat patients with relapsed/refractory multiple myeloma. The company’s CEO, Ying Huang, PhD, spoke with Pharmaceutical Executive about these results and their implications.

Traditional Chinese Medicine Compound Reduces Risk of Progression for Those With Prediabetes

Impaired glucose tolerance is a significant risk factor for developing diabetes.

Current State of the Pharma Sales and Marketing Sales Force

Industry experts, in a roundtable discussion, explore the evolution of brand engagement in the age of AI, including the growing importance of message relevance—and, for pharma, going where the information is.

The AI Influencer Ads Are Coming

Look closely. Is that a real person?

Talkspace and FitOn Team Up to Promote Mental Fitness and Launch First-Ever Mental Health Education Sessions In-App

Talkspace announced it will join forces with FitOn to provide a holistic mental health and fitness solution to employers, and showcase the power of bringing together physical and mental fitness into an everyday setting.

AllazoHealth on LinkedIn

Suzanne Shelley (she/her)'s piece for this month's Pharmaceutical Commerce Magazine covers several solutions that AllazoHealth has been pioneering for years. CEO William Grambley contributed to the subject, "Combining RWE and AI to Bend the Adherence Curve."

He shares, “Using our data-driven intelligence, we are able to drive the optimal combination of elements from the matrix that will provide the most personalized and impactful outreach for any given patient."

For more, check out
#RWE #healthcareAI #medicationadherence

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.